ABSTRACT
Objective To evaluate febrile seizure risk following monovalent COVID-19 mRNA vaccination among children aged 2-5 years.
Methods The primary analysis evaluated children who had a febrile seizure outcome in the 0-1 days following COVID-19 vaccination. A self-controlled case series analysis was performed in three commercial insurance databases to compare the risk of seizure in the risk interval (0-1 days) to a control interval (8-63 days).
The exposure of interest was receipt of dose 1 and/or dose 2 of monovalent COVID-19 mRNA vaccinations.
The primary outcome was febrile seizure (0-1 day risk interval).
A conditional Poisson regression model was used to compare outcome rates in risk and control intervals and estimate incidence rate ratios (IRR) and 95% confidence intervals (CIs). Meta-analyses were used to pool results across databases.
Results The primary meta-analysis found a statistically significant increased incidence of febrile seizure, in the 0-1 days following mRNA-1273 vaccination compared to the control interval (IRR: 2.52, 95% CI: 1.35 to 4.69, risk difference (RD)/100,000 doses = 3.22 (95%CI -0.31 to 6.75)). For the BNT162b2 vaccination, the IRR was elevated but not statistically significant (IRR: 1.41, 95%CI: 0.48 to 4.11, RD/100,000 doses = -0.25 (95%CI -2.75 to 2.24).
Conclusions Among children aged 2-5 years, the analysis showed a small elevated incidence rate ratio of febrile seizures in the 0-1 days following the mRNA-1273 vaccination. Based on the current body of scientific evidence, the safety profile of the monovalent mRNA vaccines remains favorable for use in young children.
Article Summary In this self-controlled case series study, researchers evaluated whether there is an elevated risk of febrile seizure immediately following monovalent COVID-19 mRNA vaccination.
What’s Known on This Subject The United States Food and Drug Administration previously noted a potential safety concern for seizure in children aged 2-5 years receiving the ancestral monovalent COVID-19 mRNA vaccines.
What This Study Adds In this self-controlled case series that included participants aged 2-5 years from three commercial insurance databases, the incidence rate ratio of febrile seizures was significantly elevated in the 0-1 days following mRNA-1273 administration. Absolute risk was small.
Competing Interest Statement
Both Drs Djibo and McMahill-Walraven are CVS Health employees
Clinical Protocols
Funding Statement
The US Food and Drug Administration provided funding for this study and contributed as follows: led the design of the study, interpretation of the results, writing of the manuscript, decision to submit, and made contributions to the coordination of data collection and analysis of the data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We conducted this study within the Biologics Effectiveness and Safety (BEST) Initiative. FDA Amendments Act of 2007 required that FDA develop a national electronic system for monitoring safety of FDA-regulated medical products. FDA built the Sentinel Initiative in response to the congressional requirement, and the BEST Initiative commenced as a Center for Biologics Evaluation and Research (CBER) component of Sentinel. The Office of Human Research Protection (OHRP) determined that the regulations OHRP administers (45 CFR part 46) do not apply to the activities that are included in the FDA's Sentinel Initiative.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This update includes a revised author order
Data Availability
The study protocol was posted previously. Data analyses and related documents can be made available where needed, by contacting the corresponding author. De-identified participant data will not be shared without approval from the data partners
Abbreviations
- BEST
- Biologics Effectiveness and Safety
- CBER
- Center for Biologics Evaluation and Research
- CI
- Confidence Interval
- CPT
- Current Procedural Terminology
- CVX
- IIS code indicating vaccination
- DTaP
- Diphtheria, Tetanus, Pertussis
- EUA
- Emergency Use Authorization
- FDA
- Food and Drug Administration
- HCPCS
- Healthcare Common Procedure Coding System
- ICD-10-CM
- International Classification of Diseases, Tenth Revision, Clinical Modification
- IIS
- Immunization Information System
- IRR
- Incidence Rate Ratio
- MMR/MMRV
- Measles, Mumps, Rubella/Measles, Mumps, Rubella, Varicella
- mRNA
- Messenger ribonucleic acid
- NDC
- National Drug Codes
- NRS
- Near Real-Time Surveillance
- PCV13
- Pneumococcal Conjugate Vaccine
- PPV
- Positive Predictive Value
- RD
- Risk Difference
- SAE
- Systemic Adverse Event
- SCCS
- Self-Controlled Case Series
- U.S.
- United States
- VAERS
- Vaccine Adverse Event Reporting System
